Insider Transactions in Q1 2023 at Evolus, Inc. (EOLS)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 27
2023
|
David Moatazedi Director |
SELL
Open market or private sale
|
Direct |
6,110
-0.99%
|
$48,880
$8.47 P/Share
|
|
Mar 14
2023
|
Rui Avelar Officer |
SELL
Open market or private sale
|
Direct |
14,906
-4.25%
|
$119,248
$8.47 P/Share
|
|
Mar 14
2023
|
David Moatazedi Director |
SELL
Open market or private sale
|
Direct |
64,211
-9.44%
|
$513,688
$8.47 P/Share
|
|
Feb 17
2023
|
Alphaeon 1 LLC |
SELL
Open market or private sale
|
Direct |
1,850,000
-30.5%
|
$14,800,000
$8.4 P/Share
|
|
Feb 07
2023
|
Medytox Inc. |
SELL
Open market or private sale
|
Direct |
2,187,511
-30.13%
|
$17,500,088
$8.5 P/Share
|
|
Jan 27
2023
|
Peter C Farrell Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,293
+16.11%
|
-
|
|
Jan 27
2023
|
David N Gill Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,293
+17.97%
|
-
|
|
Jan 27
2023
|
Simone Blank Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,293
+11.6%
|
-
|
|
Jan 27
2023
|
Karah Herdman Parschauer Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,293
+16.11%
|
-
|
|
Jan 27
2023
|
Vikram Malik Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,293
+9.66%
|
-
|
|
Jan 27
2023
|
Robert Hayman Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,293
+14.69%
|
-
|
|
Jan 27
2023
|
Brady Stewart Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,293
+15.62%
|
-
|
|
Jan 25
2023
|
David Moatazedi Director |
BUY
Grant, award, or other acquisition
|
Direct |
187,927
+21.66%
|
-
|
|
Jan 25
2023
|
Rui Avelar Officer |
BUY
Grant, award, or other acquisition
|
Direct |
97,642
+21.77%
|
-
|
|
Jan 25
2023
|
Sandra Beaver Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
62,642
+38.73%
|
-
|
|
Jan 20
2023
|
Medytox Inc. |
SELL
Open market or private sale
|
Indirect |
37,043
-0.51%
|
$407,473
$11.04 P/Share
|